TradingView
AlenCiken
Aug 4, 2020 10:47 AM

Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 

NASDAQ:IMUX60
Immunic, Inc.NASDAQ

Description

⋅
Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Study Meets Primary and Key Secondary Endpoints with High Statistical Significance

Statistically Significant Reduction of 62% and 70%

Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Multiple Sclerosis Patient Population -

- Company Also Reports Second Quarter 2020 Financial Results With $48.6 Million in Cash and Cash Equivalents -

finance.yahoo.com/news/immunic-inc-reports-positive-top-190000055.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1JTVVYJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAAA6N0afyvOGtkIasZaQBr1nGN86yGd-hjLGDX0B0KgNODvR_KhWRPk-Ao5Op-iaCFeErYM863SwP1L1ooEum5fr0veyleX6PZUJO5WTJRuqJm2ETwCipuNEAo-QhoN4Z08Xgi5Ja389VsNlp5YlR_NT-HiTUf_5qD8ew6PxYTuC2&_guc_consent_skip=1596537765

Fundamental AnalysisTrend AnalysisChart Patterns
More